CEL-SCI Home Page
preload preload

February 2016

CEL-SCI CEO on Fox

January 2016

CEL-SCI Shareholder Letter

Press Releases

Corporate Presentations

Press Releases

December 2, 2016
NEW STORY CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants

December 1, 2016
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

November 21, 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial

November 14, 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

October 21, 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial

September 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

September 6, 2016
NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reasons

September 2, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

August 29, 2016
NEW STORY CEL-SCI Announces the Closing of its $5 Million Registered Direct Offering

August 23, 2016
NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering

August 10, 2016
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

August 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in Julyfor Its Phase 3 Head and Neck Cancer Trial

July 11, 2016
NEW STORY CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy

July 5, 2016
CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial

June 7, 2016
CEL-SCI to Present at LD Micro Invitational

June 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial

May 31, 2016
CEL-SCI to Present At the Fifth Annual Marcum Microcap Conference

May 24, 2016
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

May 18, 2016
CEL-SCI Announces $5 Million Registered Direct Offering

May 10, 2016
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

May 2, 2016
CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial

April 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial

March 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial

February 9, 2016
CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

February 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial

January 8, 2016
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016

January 5, 2016
CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial

December 11, 2015
CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY